Immuron achieves record half yearly travelan® sales

Highlights: record half yearly travelan® sales of $2,334,969 total sales of a$2,355,580 in h1, fy24 $1,771,932 increase on h1, fy23 sales 51% higher than pre-pandemic period h1, fy20 sales melbourne, australia, jan. 16, 2024 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company is pleased to announce record half yearly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement travelan®. australia sales of travelan® increased to aud $1,853,048 in h1, fy24, compared to aud $260,205 in h1, fy23.
IMRN Ratings Summary
IMRN Quant Ranking